The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.